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BACKGROUND: AMP-activated protein kinase (AMPK, PRKA) has central roles in cellular metabolic sensing and energy balance
homeostasis, and interacts with various pathways (e.g., TP53 (p53), FASN, MTOR and MAPK3/1 (ERK)). AMP-activated protein
kinase activation is cytotoxic to cancer cells, supporting AMPK as a tumour suppressor and a potential therapeutic target. However,
no study has examined its prognostic role in colorectal cancers.
METHODS: Among 718 colon and rectal cancers, phosphorylated AMPK (p-AMPK) and p-MAPK3/1 expression was detected in 409
and 202 tumours, respectively, by immunohistochemistry. Cox proportional hazards model was used to compute mortality hazard
ratio (HR), adjusting for clinical and tumoral features, including microsatellite instability, CpG island methylator phenotype, LINE-1
methylation, and KRAS, BRAF and PIK3CA mutations.
RESULTS: Phosphorylated AMPK expression was not associated with survival among all patients. Notably, prognostic effect of p-AMPK
significantly differed by p-MAPK3/1 status (Pinteraction¼0.0017). Phosphorylated AMPK expression was associated with superior
colorectal cancer-specific survival (adjusted HR 0.42; 95% confidence interval (CI), 0.24–0.74) among p-MAPK3/1-positive cases, but
not among p-MAPK3/1-negative cases (adjusted HR 1.22; 95% CI: 0.85–1.75).
CONCLUSION: Phosphorylated AMPK expression in colorectal cancer is associated with superior prognosis among p-MAPK3/1-positive
cases, but not among p-MAPK3/1-negative cases, suggesting a possible interaction between the AMPK and MAPK pathways
influencing tumour behaviour.
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Colorectal cancer is the fourth most common malignancy and the
second most frequent cause of cancer-related death in the United
States, with approximately 50000 cancer-related deaths in 2009
(Jemal et al, 2009). Colorectal cancer arises through a multistep
carcinogenic process in which genetic and epigenetic alterations
(e.g., microsatellite instability (MSI), CpG island methylation,
mutations in KRAS, BRAF and PIK3CA) accumulate in a sequential
manner. A better understanding of molecular alterations in
colorectal cancer may be of great clinical importance. KRAS muta-
tional status of stage IV colorectal cancer is a predictive biomarker
for anti-EGFR treatment (Loupakis et al, 2009). In addition, BRAF
mutation identifies a subgroup of patients with unfavourable
prognosis (Ogino et al, 2009; Roth et al, 2010).
AMP-activated protein kinase (AMPK; PRKA, the HUGO-
approved official gene stem symbol) is a heterotrimeric serine/
threonine protein kinase, which acts as a cellular sensor for energy
balance status. AMP-activated protein kinase is phosphorylated
by its upstream kinase STK11 (LKB1) in response to an increase in
cellular AMP/ATP ratio (Shackelford and Shaw, 2009). It regulates
cell proliferation and growth by inhibition of the MTOR pathway
and fatty acid synthesis, and activation of the TP53-CDKN1A (p21)
pathway (Figure 1) (Inoki and Guan, 2009). The MAPK3/1 (extra-
cellular signal-regulated kinase (ERK)1/2) pathway is activated
by extracellular and intracellular mitogenic stimuli and has
crucial roles in cellular differentiation, proliferation and survival
(Schubbert et al, 2007). Interactions between the STK11 (LKB1)-
AMPK pathway and the MAPK3/1 pathway in human cancer cells
including colon cancer cells have been documented (Esteve-Puig
et al, 2009; Zheng et al, 2009; Kim et al, 2010). AMP-activated
protein kinase activation is cytotoxic to various cancer cell types,
and inhibits tumour growth (Buzzai et al, 2007; Zakikhani et al,
2008), supporting AMPK as a tumour suppressor and a potential
target for cancer therapy and chemoprevention (Fay et al, 2009).
Thus, better understanding of the mechanism and consequence
of AMPK activation in human cancer is increasingly important.
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status and patient prognosis in human colorectal cancer. Given
potential roles of AMPK as a regulator of cellular metabolism and
a tumour suppressor related to cellular signaling pathways (e.g.,
the MAPK3/1 pathway), we hypothesised that AMPK might
interact with MAPK3/1 to modify tumour behaviour.
To test this hypothesis, we utilised a database of 718 stage I–IV
colorectal cancers in two prospective cohort studies, and examined
the prognostic role of phosphorylated-AMPK expression and
modifying effect of MAPK3/1. As a result of our database with
other tumoral variables including FASN, TP53, KRAS, BRAF and
PIK3CA mutations, MSI, the CpG island methylator phenotype
(CIMP) and LINE-1 methylation, we could examine the relation-
ship between AMPK status and other molecular features, as well as
interactive prognostic effect of AMPK and other molecular events.
MATERIALS AND METHODS
Study group
We utilised the databases of two independent, prospective cohort
studies; the Nurses’ Health Study (N¼121701 women followed
since 1976), and the Health Professionals Follow-Up Study
(N¼51529 men followed since 1986) (Chan et al, 2007). A subset
of the cohort participants developed colorectal cancers during
prospective follow-up. We collected paraffin-embedded tissue
blocks from hospitals where patients underwent tumour resec-
tions. We excluded cases for which preoperative treatment was
administered. Tissue sections from all colorectal cancer cases were
reviewed by a pathologist (SO) unaware of other data. The tumour
grade was categorised as low vs high (X50 vs o50% gland
formation). The type of tumour border (expansile or infiltrative)
was categorised as previously published criteria (Ogino et al,
2006e). On the basis of the availability of adequate tissue
specimens and follow-up data, a total of 718 colorectal cancers
(diagnosed up to 2004) were included. Patients were observed
until death or 30 June 2008, whichever came first. Among our
cohort studies, there was no significant difference in demographic
features between cases with tissue available and those without
available tissue (Chan et al, 2007). This current analysis represents
a new analysis of p-AMPK and p-MAPK3/1 on the existing
colorectal cancer database that has been previously characterised
for CIMP, MSI, KRAS, BRAF, PIK3CA, LINE-1 methylation and
clinical outcome (Ogino et al, 2007, 2008b, 2009). However, in any
of our previous studies, we have neither examined AMPK or
MAPK3/1 expression. Informed consent was obtained from all
study subjects. Tissue collection and analyses were approved by
the Harvard School of Public Health and Brigham and Women’s
Hospital Institutional Review Boards.
Sequencing of KRAS, BRAF and PIK3CA and MSI analysis
DNA was extracted from tumour tissue, and PCR and pyrosequen-
cing targeted for KRAS (codons 12 and 13) (Ogino et al, 2005),
BRAF (codon 600) (Ogino et al, 2006d) and PIK3CA (exons 9
and 20) were performed (Nosho et al, 2008b). The status of MSI
was determined by analysing variability in the length of the
microsatellite markers from tumour DNA compared with normal
DNA. We used D2S123, D5S346, D17S250, BAT25, BAT26 BAT40,
D18S55, D18S56, D18S67 and D18S487 (Ogino et al, 2006a).
Microsatellite instability-high was defined as the presence of
instability in X30% of the markers, and MSI-low/microsatellite
stability (MSS) as instability in 0–29% of the markers according to
the Bethesda guideline (Boland et al, 1998).
Methylation analyses for CpG islands and LINE-1
Using validated bisulphite DNA treatment and real-time PCR
(MethyLight), we quantified DNA methylation in eight CIMP-
specific promoters (CACNA1G, CDKN2A (p16), CRABP1, IGF2,
MLH1, NEUROG1, RUNX3 and SOCS1) (Weisenberger et al, 2006;
Ogino et al, 2006c, 2007). The CIMP-high was defined as the
presence of X6 out of 8 methylated promoters, CIMP-low/0
as 0 out of 8–5 out of 8 methylated promoters, based on a
distribution of tumours and BRAF and KRAS mutation frequencies
(Ogino et al, 2007). Concordance between our eight-marker panel
and the Weisenberger panel (Weisenberger et al, 2006) was very
high (99%, k¼0.94, Po0.0001) (Nosho et al, 2008a). In order to
accurately quantify relatively high methylation levels in LINE-1, we
utilised pyrosequencing (Ogino et al, 2008a; Irahara et al, 2010).
Immunohistochemistry
Tissue microarrays were constructed as previously described
(Ogino et al, 2006b). Methods of immunohistochemistry were
previously described for TP53 and FASN (fatty acid synthase)
(Ogino et al, 2006a, 2008c). For AMP-activated protein kinase
(AMPK, PRKA), we evaluated PRKAA (AMPKa) Thr172 phos-
phorylation status (Figure 2). Deparaffinised tissue sections
in Antigen Retrieval Citra Solution (Biogenex Laboratories,
San Ramon, CA, USA) were treated with microwave in a pressure
cooker (25min). Tissue sections were incubated with 5% normal
goat serum (Vector Laboratories, Burlingame, CA, USA) in
phosphate-buffered saline (30min). Primary antibody against
p-AMPK (rabbit monoclonal anti-phospho-AMPKa (Thr172)
(40H9), 1:100 dilution; Cell Signaling Technology, Boston, MA,
USA) was applied (Ji et al, 2007; Contreras et al, 2008; Hadad et al,
2009; Vazquez-Martin et al, 2009; Zheng et al, 2009), and the slides
were maintained at 41C for overnight, followed by rabbit secon-
dary antibody (Vector Laboratories) (60min), an avidin–biotin
complex conjugate (Vector Laboratories) (60min), diamino-
benzidine (5min) and methyl-green counterstain. Cytoplasmic
p-AMPK expression was recorded as no expression, weak
expression or moderate/strong expression with the percentage of
positive tumour cells. The CIMP status reflects global epigenomic
aberrations in tumour cells (Ogino and Goel, 2008) and may influ-
ence energy sensing status of cancer cells. Indeed, epidemiological
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Figure 1 Schematic representation of the AMPK pathway in relation to
various molecules. Arrows and lines indicate the pathways potentially
related with the complex interaction between AMPK and MAPK3/1. Circles
indicate the tissue markers analysed in our current study.
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metabolism in colorectal cancer; high intake of high-fat dairy
products is associated with CIMP-high rectal cancers (Slattery
et al, 2010) and exposure to a period of severe transient energy
restriction during adolescence is inversely associated with the risk
of having a CIMP-high tumour later in life (Hughes et al, 2009). In
addition, the relationship between CIMP and a molecular
alteration related to energy metabolism (e.g., SIRT1) has been
reported (Nosho et al, 2009). Thus, we explored the use of CIMP
status to determine a cutoff for p-AMPK positivity; there was no
alternative biologically based method in our cohort studies. First,
we categorised tumours according to intensity of p-AMPK and the
fraction of p-AMPK-expressing cells. In our initial exploratory
analysis, we randomly selected 358 tumours as a training set,
leaving the remaining 360 tumours as a validation set. Using the
training set, the frequency of CIMP-high in each category was: 25%
(29 out of 117) in tumours with no expression; 21% (11 out of 53)
in tumours with weak expression in 1–19% of tumour cells; 12%
(14 out of 117) in tumours with weak expression in 20–100% of
cells; 7.8% (5 out of 64) in tumours with moderate or strong
expression. Thus, p-AMPK positivity was defined as the presence
of weak cytoplasmic expression in X20% of tumour cells or
moderate/strong expression in any fraction of tumour cells. In the
remaining validation set, p-AMPK expression defined by the
training set was inversely associated with CIMP-high (odds ratio
(OR) 0.45; 95% confidence interval (CI): 0.25–0.83; P¼0.0094),
validating the cutoff although it might not be the most biologically
reasonable cutoff. In addition, to evaluate whether p-AMPK
expressions in tumour centre and invasive front were different,
we stained 20 whole tissue sections for p-AMPK and recorded
p-AMPK expression status of both tumour centre and tumour
invasive front.
For phosphorylated-MAPK3/1 (p-MAPK3/1), the same protocol
with p-AMPK was used except for primary antibody (rabbit mono-
clonal anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Thr204)
(20G11), 1:100 dilution; Cell Signaling Technology). Nuclear
p-MAPK3/1 expression was recorded as no, weak, moderate or
strong expression with the percentage of positive tumour cells.
Considering that MAPK3/1 is downstream of the RAF pathway,
we used BRAF mutation frequency to determine a cutoff for
p-MAPK3/1 positivity. First, we categorised tumours according
to the intensity of p-MAPK3/1 expression. Using the training set,
the frequency of BRAF mutation in each category was: 17% (35 out
of 206) in tumours with no expression; 8.5% (6 out of 71) in
tumours with weak expression; 7.0% (4 out of 57) in tumours with
moderate or strong expression. Thus, p-MAPK3/1 positivity was
defined as weak/moderate/strong expression. In the remaining
validation set, p-MAPK3/1 expression defined by the training set
was inversely associated with BRAF mutation (OR 0.42; 95% CI:
0.20–0.90; P¼0.023), validating the cutoff although it might not
be the most biologically reasonable cutoff.
Appropriate positive and negative controls were included in
each run of immunohistochemistry. Each immunohistochemical
maker was interpreted by one of the investigators (p-AMPK and
p-MAPK3/1 by YB; TP53 and FASN by SO) unaware of other
data. For agreement studies, a random selection of 108–246 cases
was examined for each marker by a second observer (by KN)
unaware of other data. The concordance between the two observers
(all Po0.0001) was 0.82 (k¼0.63; N¼137) for p-AMPK, 0.86
(k¼0.70; N¼137) for p-MAPK3/1, 0.87 (k¼0.75; N¼108) for
TP53 and 0.93 (k¼0.57; N¼246) for FASN, indicating good-to-
substantial agreement.
Statistical analysis
For all statistical analyses, we used SAS program (Version 9.1, SAS
Institute, Cary, NC, USA). All P-values were two-sided, and
statistical significance was set at P¼0.05. Nonetheless, when we
performed multiple hypothesis testing, a P-value for significance
was adjusted by Bonferroni correction to P¼0.0029 (¼0.05/17).
For categorical data, the w
2 test was performed. For survival
analysis, Kaplan–Meier method and log-rank test was used. For
analyses of colorectal cancer-specific mortality, deaths as a result
of causes other than colorectal cancer were censored. To assess
independent effect of p-AMPK on mortality, tumour stage (I, IIA,
IIB, IIIA, IIIB, IIIC, IV, unknown) was used as a stratifying variable
Figure 2 Phosphorylated AMPK and p-MAPK3/1 expression in colorectal cancer. (A) Positive for p-AMPK cytoplasmic expression (arrowheads).
(B) Negative for p-AMPK expression (white arrowheads). (C) Positive for p-MAPK3/1 nuclear expression (white arrows). (D) Negative for p-MAPK3/1
expression (block arrow). Stromal cells serve as an internal positive control for p-MAPK3/1 expression (arrow).
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command to avoid residual confounding and overfitting. We
constructed a multivariate, stage-stratified Cox proportional
hazards model to compute a hazard ratio (HR) according to
p-AMPK status, initially including sex, age at diagnosis (contin-
uous), body mass index (BMI, o30 vs X30kgm
–2), family history
of colorectal cancer in any first-degree relative (present vs absent),
tumour location (rectum vs colon), tumour grade (low vs high),
tumour border (infiltrative vs expansile), CIMP (high vs low/0),
MSI (high vs low/MSS), LINE-1 methylation (continuous), BRAF,
KRAS, PIK3CA, TP53 and FASN. A backward stepwise elimination
with a threshold of P¼0.20 was used to select variables in the final
model. For cases with missing information in any of categorical
variables (tumour location (1.2%), MSI (1.9%), BRAF (1.7%),
KRAS (1.3%), PIK3CA (10%), TP53 (0.6%) and FASN (1.0%)), we
included those cases in a majority category of a given covariate to
avoid overfitting. We confirmed that excluding cases with missing
information in any of the covariates did not substantially alter
results (data not shown). The proportionality of hazard assump-
tion was satisfied by evaluating time-dependent variables, which
were the cross-product of the AMPK variable and survival time
(P40.05). An interaction was assessed by including the cross
product of p-AMPK variable and another variable of interest
(without data-missing cases) in a multivariate Cox model, and the
Wald test was performed. Backward stepwise elimination with a
threshold of P¼0.20 was used to select variables in the final
model. A P-value for significance was adjusted to P¼0.0029 by
Bonferroni correction for multiple hypothesis testing.
RESULTS
AMPK expression in colorectal cancer
To evaluate whether phosphorylated AMPK (p-AMPK, p-PRKA)
expressions in tumour centre and invasive front were different,
we stained 20 whole tissue sections for p-AMPK and recorded
p-AMPK expression status of both tumour centre and tumour
invasive front. In 16 of 20 sections, tumour centre and tumour
invasive front showed concordant expression status, indicating
that p-AMPK expressions in tumour centre and invasive front were
not different in most cases. Furthermore, whole tissue section-
based expression status and TMA-based expression status were
concordant in 18 of 20 cases, indicating that expression status
determined using TMA represented expression status of tumour as
a whole in a vast majority of cases.
Among 718 colorectal cancers in the two prospective cohort
studies, we detected p-AMPK in 409 tumours (57%) by immuno-
histochemistry. Phosphorylated AMPK expression was associated
with p-MAPK3/1 expression (Po0.0001) and inversely with high
tumour grade (P¼0.0009), MSI-high (P¼0.0021) and CIMP-high
(Po0.0001) (Table 1).
AMPK expression and prognosis in colorectal cancer
Among the 718 patients (with median follow-up of 129 months for
censored patients), there were 306 deaths, including 194 colorectal
cancer-specific deaths. In Kaplan–Meier or Cox regression
analysis, p-AMPK status was not significantly associated with
colorectal cancer-specific or overall survival among all eligible
patients (Figure 3A, Table 2).
Modifying effect of p-MAPK3/1 expression on p-AMPK
expression in survival analysis
Considering experimental data on the interaction between AMPK
and MAPK3/1 (Esteve-Puig et al, 2009; Zheng et al, 2009; Kim et al,
2010), we assessed whether p-MAPK3/1 status could modify the
prognostic effect of p-AMPK expression. We found a significant
modifying effect of p-MAPK3/1 expression on the relation between
p-AMPK expression and mortality (Pinteraction¼0.0017 (for color-
ectal cancer-specific mortality) and Pinteraction¼0.0026 (for overall
mortality)). Among patients with p-MAPK3/1-positive tumour,
p-AMPK expression was associated with a significant decrease
in colorectal cancer-specific mortality (adjusted HR 0.42; 95% CI:
0.24–0.74), whereas p-AMPK expression was not significantly
related with prognosis among patients with p-MAPK3/1-negative
tumour (adjusted HR 1.22; 95% CI: 0.85–1.75; p-AMPK-positive vs
negative) (Table 3).
In Kaplan–Meier method, the differential prognostic effect of
p-AMPK expression according to p-MAPK3/1 expression status
was evident (Figure 3A). Phosphorylated AMPK expression was
associated with longer colorectal cancer-specific survival (log-rank
P¼0.0006) among p-MAPK3/1-positive cases, whereas p-AMPK
expression was not significantly associated with survival among
p-MAPK3/1-negative cases (log-rank P¼0.45).
Prognostic effect of p-MAPK3/1 expression in strata
of p-AMPK status
In Kaplan–Meier analysis, p-MAPK3/1 was not significantly
associated with colorectal cancer-specific survival (log-rank
P¼0.31) (Figure 3B) or overall survival (log-rank P¼0.68).
In light of the significant interaction between p-AMPK and
p-MAPK3/1 (Pinteraction¼0.0017), we examined the prognostic
effect of p-MAPK3/1 expression in strata of p-AMPK expression
status. Among p-AMPK-negative cases, p-MAPK3/1 expression
was significantly associated with inferior colorectal cancer-specific
survival (adjusted HR 1.94; 95% CI: 1.17–3.24; p-MAPK3/1-
positive vs negative tumours). In contrast, among p-AMPK-
positive cases, p-MAPK3/1 expression was significantly associated
with superior colorectal cancer-specific survival (adjusted HR 0.55;
95% CI: 0.35–0.86) (Table 3). A similar interaction was observed
in overall mortality analysis (Pinteraction¼0.0026).
Stratified analysis of p-AMPK expression and mortality
We examined whether the influence of p-AMPK expression on
colorectal cancer-specific survival was modified by any of the other
variables including sex, age, BMI, family history of colorectal
cancer, tumour location, stage, tumour grade, CIMP, MSI, BRAF,
KRAS, PIK3CA, LINE-1 methylation, TP53 and FASN. We did
not observe a significant modifying effect by any of the variables
(all Pinteraction40.10). Notably, there was no significant inter-
action between p-AMPK and mutation in KRAS or BRAF
(Pinteraction¼0.12 for BRAF and Pinteraction¼0.30 for KRAS).
DISCUSSION
We conducted this study to examine prognostic significance of
p-AMPK (phosphorylated AMP-activated protein kinase; p-PRKA)
expression in a large cohort of colorectal cancers. To our best
knowledge, no previous study has examined its prognostic role in
human colorectal cancer. Considering a pivotal role of AMPK as a
regulator of cellular metabolism and the relationship of AMPK
with the MAPK3/1 (ERK1/2) pathway and other signaling path-
ways, we hypothesised that cellular AMPK might interact with
MAPK3/1 to modify tumour behaviour. Notably, we found that the
prognostic effect of p-AMPK expression differed according to
p-MAPK3/1 status. Phosphorylated AMPK expression was asso-
ciated with superior survival among p-MAPK3/1-positive cases,
but not among p-MAPK3/1-negative cases. Our results support
an interaction between the AMPK and MAPK3/1 pathways in
colorectal cancer cells to modify tumour behaviour.
Examining molecular changes or prognostic factors is impor-
tant in cancer research (Fluge et al, 2009; Gaber et al, 2009;
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2010; Zlobec et al, 2010). Accumulating evidence suggests that
AMPK acts as a tumour suppressor. STK11 (LKB1) has been
identified as an upstream activator of AMPK (Shackelford and
Shaw, 2009), and TSC2, which is a negative regulator of MTOR, is a
downstream effector of AMPK (Inoki and Guan, 2009). Experi-
mental studies have shown that AMPK activation inhibits cancer
cell proliferation and growth (Buzzai et al, 2007; Zakikhani et al,
2008). In a study using 354 breast cancers (Hadad et al, 2009),
p-AMPK expression was not significantly associated with prog-
nosis, but modifying effect of MAPK3/1 was not examined. To our
knowledge, no previous study has examined the prognostic role
of AMPK in colorectal cancer.
Considering experimental data on the link between the STK11
(LKB1)-AMPK and MAPK3/1 pathways, the modifying effect
of MAPK3/1 on AMPK may not be surprising. In colon cancer
cells, AMPK potentially inhibits the MAPK3/1 pathway; inhibition
of AMPK by expressing a dominant-negative form potentiates
MAPK3/1 activation under glucose deprivation (Kim et al, 2010).
Selenium, an essential trace element, blocks the carcinogenic
agent-induced MAPK3/1 activation via AMPK (Hwang et al, 2006).
AMP-activated protein kinase is rapidly activated by cisplatin and
suppresses an apoptotic signal via MAPK3/1 in colon cancer cells
(Kim et al, 2008). A study using melanoma cells (Zheng et al, 2009)
has shown that the MAPK3/1 pathway phosphorylates STK11 on
Ser325 and Ser428 and promotes the uncoupling of AMPK from
STK11, which negatively regulates AMPK. Regulation of AMPK
activity by the MAPK3/1 pathway, independent of STK11 Ser428
phosphorylation, has also been reported (Esteve-Puig et al, 2009).
In fibroblast cells, AMPK differentially inhibits the MAPK3/1
pathway by inhibiting RAS activation or stimulating the
RAS-independent pathway in response to cellular energy status
(Kim et al, 2001). We should also consider the complex
TSC2-MTOR axis-mediated linkage. AMP-activated protein kinase
suppresses MTOR activity directly by phosphorylating MTOR at
Thr2446 and indirectly by phosphorylating TSC2 at Thr1227 and
Ser1345 and increasing the activity of TSC-complex (Inoki and
Guan, 2009). MAPK3/1 increases MTOR activity by phosphorylat-
ing TSC2 at Ser540 and Ser664, which causes the attenuation of
TSC2 (Ma et al, 2005). Our findings may support the hypothesis
that AMPK activation can make a strong impact on tumour
behaviour as the ‘brake’ only when MAPK3/1 is active. Additional
studies are needed to confirm our findings and elucidate the exact
mechanism of effect of MAPK3/1 on AMPK to modify tumour
behaviour.
Our study has shown that MAPK3/1 activation has a differential
effect on patient mortality according to AMPK status; p-MAPK3/1
Table 1 p-AMPK expression in colorectal cancer, and clinical, pathologic
and molecular features
Clinical, pathologic
p-AMPK
expression
or molecular feature Total N Negative Positive P-value
All cases 718 309 409
Sex 0.051
Male 259 (36%) 99 (32%) 160 (39%)
Female 459 (64%) 210 (68%) 249 (61%)
Age (years)
p59 143 (20%) 71 (23%) 72 (18%) 0.071
60–69 301 (42%) 116 (38%) 185 (45%)
X70 274 (38%) 122 (39%) 152 (37%)
BMI 0.69
o30kgm
–2 594 (83%) 254 (82%) 340 (83%)
X30kgm
–2 123 (17%) 55 (18%) 68 (17%)
Family history of colorectal cancer 0.66
( ) 554 (77%) 236 (76%) 318 (78%)
(+) 164 (23%) 73 (24%) 91 (22%)
Tumour location 0.61
Proximal colon
(cecum to transverse)
347 (49%) 155 (51%) 192 (48%)
Distal colon (splenic flexure
to sigmoid)
220 (31%) 89 (29%) 131 (32%)
Rectum 140 (20%) 61 (20%) 79 (20%)
Stage 0.16
I 160 (22%) 55 (18%) 105 (26%)
II 214 (30%) 100 (32%) 114 (28%)
III 204 (28%) 91 (29%) 113 (28%)
IV 101 (14%) 45 (15%) 56 (14%)
Unknown 39 (5.4%) 18 (5.8%) 21 (5.1%)
Tumour grade 0.0009
Low 655 (92%) 269 (88%) 386 (95%)
High 60 (8.4%) 38 (12%) 22 (5.4%)
Tumour border 0.80
Expansile 543 (86%) 237 (86%) 306 (85%)
Infiltrative 90 (14%) 38 (14%) 52 (15%)
p-MAPK3/1 expression
( ) 469 (70%) 227 (80%) 242 (63%) o0.0001
(+) 202 (30%) 57 (20%) 145 (37%)
TP53 expression 0.055
( ) 423 (59%) 194 (63%) 229 (56%)
(+) 290 (41%) 112 (37%) 178 (44%)
FASN expression 0.024
( ) 597 (84%) 267 (88%) 330 (81%)
(+) 114 (16%) 38 (12%) 76 (19%)
MSI 0.0021
MSI-low/MSS 591 (84%) 242 (79%) 349 (88%)
MSI-high 113 (16%) 64 (21%) 49 (12%)
CIMP
CIMP-low/0 596 (85%) 237 (78%) 359 (89%) o0.0001
CIMP-high 109 (15%) 66 (22%) 43 (11%)
LINE-1 methylation
X70% 121 (17%) 53 (18%) 68 (17%) 0.16
50–69% 497 (71%) 220 (74%) 277 (70%)
o50% 79 (11%) 26 (8.7%) 53 (13%)
BRAF mutation 0.048
( ) 602 (85%) 250 (82%) 352 (88%)
(+) 104 (15%) 54(18%) 50 (12%)
Table 1 (Continued)
Clinical, pathologic
p-AMPK
expression
or molecular feature Total N Negative Positive P-value
KRAS mutation 0.26
( ) 438 (62%) 195 (64%) 243 (60%)
(+) 271 (38%) 109 (36%) 162 (40%)
PIK3CA mutation 0.79
( ) 538 (84%) 236 (84%) 302 (83%)
(+) 106 (16%) 45 (16%) 61 (17%)
Abbreviations: BMI¼body mass index; CIMP¼CpG island methylator phenotype;
FASN¼fatty acid synthase; MSI¼microsatellite instability; MSS¼microsatellite
stable; p-AMPK¼phosphorylated AMP-activated protein kinase; p-MAPK3/1
¼phosphorylated mitogen-activated protein kinase. % Number indicated the
proportion of cases with a given clinical, pathologic or molecular feature among all
cases, p-AMPK-negative cases or p-AMPK-positive cases.
AMPK, MAPK3/1 and prognosis in colorectal cancer
Y Baba et al
1029
British Journal of Cancer (2010) 103(7), 1025–1033 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sexpression is associated with good prognosis among p-AMPK-
positive patients, but with poor prognosis among p-AMPK-
negative patients. It remains controversial how MAPK3/1 activa-
tion affects behaviour of different cancers (Milde-Langosch et al,
2005; Pelloski et al, 2006). A study on 135 colorectal cancers
has shown that p-MAPK3/1 expression is associated with poor
prognosis (Schmitz et al, 2007). In contrast to that study (N¼135),
our study evaluated the expression status of both p-MAPK3/1 and
p-AMPK in a much larger cohort of 718 colorectal cancers. In
addition, we assessed the interactive effect of p-MAPK3/1 and
p-AMPK expression independent of other molecular events that
have been documented to be critical in colorectal carcinogenesis.
Recently, AMPK has been proposed as a potential target for
cancer prevention and treatment, and various AMPK activators
have been preclinically assessed (Fay et al, 2009). Among them,
metformin, a widely used anti-diabetic drug, has shown promising
results (Buzzai et al, 2007; Zakikhani et al, 2008). Metformin may
have two properties of potential oncologic relevance: it has a
direct, STK11-AMPK pathway-dependent growth inhibitory effect
and decreases systemic insulin levels (Pollak, 2008). Interestingly,
two observational studies have shown that diabetic patients treated
with metformin experienced a lower incidence of any kind of
cancer and a lower cancer-related mortality (Evans et al, 2005;
Bowker et al, 2006). Hereafter, in clinical trial of this drug,
examining AMPK status in cancer tissue might be important. In
this regard, our findings may have clinical implications. In
addition, drugs targeting the MAPK3/1 pathway are intensively
being developed and tested in clinical trials for various human
cancers (Beeram et al, 2005). Although the usefulness of MAPK3/1
expression as a biomarker for sensitivity to these drugs is
uncertain (Yeh et al, 2009), further understanding of the linkage
between the AMPK and MAPK3/1 pathways could potentially
provide useful information for refinement of therapeutic strategies.
We found significant relations of p-AMPK expression with
MSI-high and CIMP-high. MSI and CIMP status reflect global
genomic and epigenomic aberrations in tumour cells, and hence,
p-MAPK3/1-positive cases All cases p-MAPK3/1-negative cases
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Figure 3 Kaplan–Meier curves for colorectal cancer-specific survival. (A) p-AMPK status and survival of colorectal cancer patients. The left panel includes
all eligible cases, the middle panel includes p-MAPK3/1-positive cases, and the right panel includes p-MAPK3/1-negative cases. (B) p-MAPK3/1 status and
survival of colorectal cancer patients. The left panel includes all eligible cases, the middle panel includes p-AMPK-positive cases, and the right panel includes
p-AMPK-negative cases.
Table 2 p-AMPK status in colorectal cancer and patient mortality
Colorectal cancer-specific mortality Overall mortality
AMPK
status
Total
N
Deaths/
person-years
Univariate
HR (95% CI)
Multivariate stage-matched
HR (95% CI)
Deaths/
person-years
Univariate
HR (95% CI)
Multivariate stage-matched
HR (95% CI)
p-AMPK ( ) 309 86/2164 1 (referent) 1 (referent) 125/2164 1 (referent) 1 (referent)
p-AMPK (+) 409 108/2952 0.84 (0.61–1.17) 0.95 (0.71–1.28) 181/2952 1.08 (0.84–1.39) 1.12 (0.89–1.42)
Abbreviations: BMI¼body mass index; CI¼confidence interval; HR¼hazard ratio; CIMP¼CpG island methylator phenotype; FASN¼fatty acid synthase; MSI¼microsatellite
instability; p-AMPK¼phosphorylated AMP-activated protein kinase. The multivariate, stage-matched (stratified) Cox model initially included sex, age at diagnosis, year of
diagnosis, BMI, family history of colorectal cancer, tumour location, tumour grade, tumour border, CIMP, MSI, LINE-1 methylation, BRAF, KRAS, PIK3CA, TP53 and FASN.
A backward stepwise elimination with a threshold of P¼0.20 was used to select variables in the final model. Stage adjustment (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was done
using the ‘strata’ option in the SAS ‘proc phreg’ command.
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sare associated with various clinical, pathologic and molecular
features (Ogino and Goel, 2008). Considering the known relation-
ship between MSI and/or CIMP and molecular alterations related
to energy metabolism (Ogino et al, 2007b; Nosho et al, 2009), MSI
and CIMP may influence energy sensing status of cancer cells.
There are limitations in this study. For example, data on
cancer treatment were limited. Nonetheless, it is unlikely that
chemotherapy use substantially differed according to AMPK status
in tumour, because such data were unavailable for treatment
decision making. In addition, our multivariate survival analysis
finely adjusted for disease stage (I, IIA, IIB, IIIA, IIIB, IIIC, IV,
unknown), on which treatment decision making was mostly based.
As another limitation, beyond cause of mortality, data on cancer
recurrence were unavailable in these cohort studies. Nonetheless,
colorectal cancer-specific survival might be a reasonable surrogate
of colorectal cancer-specific outcome. Furthermore, the cutoffs for
p-AMPK and p-MAPK3/1 used in this current study need to be
validated in an independent data set.
There are advantages in utilising the database of the two
prospective cohort studies, the Nurses’ Health Study and the
Health Professionals Follow-Up Study, to examine prognostic
significance of tumour AMPK expression. Anthropometric mea-
surements, family history, cancer staging, and other clinical,
pathologic, and tumour molecular data were prospectively
collected, blinded to patient outcome. Cohort participants who
developed cancer were treated at hospitals throughout the United
States, and thus more representative colorectal cancers in the US
population than patients in one to several academic hospitals.
There was no demographic difference between cases with tumour
tissue analysed and those without tumour tissue analysed (Chan
et al, 2007). Finally, our rich tumour database enabled us to
simultaneously assess pathologic and tumoral molecular correlates
and control for confounding by a number of tumoral molecular
alterations.
In summary, we have shown that AMPK activation is associated
with good prognosis among MAPK3/1-activated colorectal cancer
patients, while AMPK activation is not associated with prognosis
among MAPK3/1-inactive cancer patients. Additional studies are
necessary to confirm our observations and to elucidate exact
mechanisms by which AMPK and MAPK3/1 interact and affect
tumour behaviour. This possible interaction between the AMPK
and MAPK3/1 pathways may have considerable implications
because both pathways are potential targets for cancer treatment
and prevention. In this regard, examining AMPK and MAPK3/1
status in cancer tissue may be important in future clinical trials.
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Table 3 p-AMPK status and patient mortality in strata of p-MAPK3/1 status (upper rows) and p-MAPK3/1 status and patient mortality in strata of p-AMPK
status (lower rows)
Colorectal cancer-specific mortality Overall mortality
No. of
deaths/cases
Univariate
HR (95% CI)
Multivariate stage-matched
HR (95% CI)
No. of
deaths/cases
Univariate
HR (95% CI)
Multivariate stage-matched
HR (95% CI)
p-MAPK3/1 ( )
p-AMPK ( ) 59/227 1 (referent) 1 (referent) 84/227 1 (referent) 1 (referent)
p-AMPK (+) 72/242 1.14 (0.81–1.61) 1.22 (0.85–1.75) 106/242 1.20 (0.90–1.60) 1.31 (0.98–1.76)
p-MAPK3/1 (+)
n p-AMPK ( ) 23/57 1 (referent) 1 (referent) 32/57 1 (referent) 1 (referent)
p-AMPK (+) 27/145 0.39 (0.23–0.69) 0.42 (0.24–0.74) 62/145 0.64 (0.42–0.98) 0.65 (0.42–1.01)
p-AMPK ( )
n p-MAPK3/1 ( ) 59/227 1 (referent) 1 (referent) 84/227 1 (referent) 1 (referent)
p-MAPK3/1 (+) 23/57 1.75 (1.08–2.82) 1.94 (1.17–3.24) 32/57 1.67 (1.12–2.50) 1.88 (1.23–2.86)
p-AMPK (+)
n p-MAPK3/1 ( ) 72/242 1 (referent) 1 (referent) 106/242 1 (referent) 1 (referent)
p-MAPK3/1 (+) 27/145 0.55 (0.36–0.85) 0.55 (0.35–0.86) 62/145 0.84 (0.62–1.14) 0.80 (0.58–1.10)
Pinteraction (p-AMPK and p-MAPK3/1) 0.0014 0.0017 0.016 0.0026
Abbreviations: BMI¼body mass index; CI¼confidence interval; HR¼hazard ratio; p-AMPK¼phosphorylated AMP-activated protein kinase; p-MAPK3/1¼phosphorylated
mitogen-activated protein kinase. The multivariate, stage-matched (stratified) Cox model included p-AMPK variable stratified by p-MAPK3/1 status (or p-MAPK3/1 variable
stratified by p-AMPK status), sex, age, year of diagnosis, BMI, tumour location, tumour grade, tumour border, CIMP, MSI, LINE-1 methylation, BRAF, KRAS, PIK3CA, TP53 and
FASN. A backward stepwise elimination with a threshold of P¼0.20 was used to select variables in the final model. Stage adjustment (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was
done using the ‘strata’ option in the SAS ‘proc phreg’ command.
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